vs

Side-by-side financial comparison of STANDARD BIOTOOLS INC. (LAB) and Maison Solutions Inc. (MSS). Click either name above to swap in a different company.

Maison Solutions Inc. is the larger business by last-quarter revenue ($27.6M vs $19.6M, roughly 1.4× STANDARD BIOTOOLS INC.). Maison Solutions Inc. runs the higher net margin — -18.0% vs -177.4%, a 159.4% gap on every dollar of revenue. On growth, Maison Solutions Inc. posted the faster year-over-year revenue change (-10.9% vs -11.5%). Over the past eight quarters, Maison Solutions Inc.'s revenue compounded faster (42.5% CAGR vs -12.2%).

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

Maison Solutions Inc. is a specialty home goods retail company that provides a diverse portfolio of stylish, affordably priced furniture, home decor items, and daily household products. Its primary market is the Guangdong-Hong Kong-Macao Greater Bay Area in China, serving mass consumers through both offline physical stores and online e-commerce channels.

LAB vs MSS — Head-to-Head

Bigger by revenue
MSS
MSS
1.4× larger
MSS
$27.6M
$19.6M
LAB
Growing faster (revenue YoY)
MSS
MSS
+0.5% gap
MSS
-10.9%
-11.5%
LAB
Higher net margin
MSS
MSS
159.4% more per $
MSS
-18.0%
-177.4%
LAB
Faster 2-yr revenue CAGR
MSS
MSS
Annualised
MSS
42.5%
-12.2%
LAB

Income Statement — Q3 FY2025 vs Q2 FY2026

Metric
LAB
LAB
MSS
MSS
Revenue
$19.6M
$27.6M
Net Profit
$-34.7M
$-5.0M
Gross Margin
48.5%
23.4%
Operating Margin
-168.5%
-4.9%
Net Margin
-177.4%
-18.0%
Revenue YoY
-11.5%
-10.9%
Net Profit YoY
-28.8%
-1840.5%
EPS (diluted)
$-0.09
$-0.23

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LAB
LAB
MSS
MSS
Q4 25
$27.6M
Q3 25
$19.6M
$27.2M
Q2 25
$21.8M
$34.4M
Q1 25
$40.8M
$32.3M
Q4 24
$29.4M
Q3 24
$22.1M
$28.2M
Q2 24
$22.5M
$16.9M
Q1 24
$45.5M
$13.6M
Net Profit
LAB
LAB
MSS
MSS
Q4 25
$-5.0M
Q3 25
$-34.7M
$-1.5M
Q2 25
$-33.5M
$-287.4K
Q1 25
$-26.0M
$1.0M
Q4 24
$-256.0K
Q3 24
$-26.9M
$700.9K
Q2 24
$-45.7M
$-2.8M
Q1 24
$-32.2M
$-549.0K
Gross Margin
LAB
LAB
MSS
MSS
Q4 25
23.4%
Q3 25
48.5%
24.1%
Q2 25
48.8%
9.5%
Q1 25
48.4%
21.8%
Q4 24
26.9%
Q3 24
54.9%
28.9%
Q2 24
46.1%
13.0%
Q1 24
53.1%
23.4%
Operating Margin
LAB
LAB
MSS
MSS
Q4 25
-4.9%
Q3 25
-168.5%
0.7%
Q2 25
-118.1%
-15.9%
Q1 25
-80.8%
3.7%
Q4 24
3.2%
Q3 24
-120.9%
7.3%
Q2 24
-134.5%
-14.4%
Q1 24
-132.2%
-2.3%
Net Margin
LAB
LAB
MSS
MSS
Q4 25
-18.0%
Q3 25
-177.4%
-5.7%
Q2 25
-153.7%
-0.8%
Q1 25
-63.8%
3.1%
Q4 24
-0.9%
Q3 24
-122.0%
2.5%
Q2 24
-203.3%
-16.4%
Q1 24
-70.6%
-4.0%
EPS (diluted)
LAB
LAB
MSS
MSS
Q4 25
$-0.23
Q3 25
$-0.09
$-0.08
Q2 25
$-0.09
$-0.02
Q1 25
$-0.07
$0.06
Q4 24
$-0.01
Q3 24
$-0.07
$0.04
Q2 24
$-0.12
$-0.16
Q1 24
$-0.27
$-0.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LAB
LAB
MSS
MSS
Cash + ST InvestmentsLiquidity on hand
$129.4M
Total DebtLower is stronger
$2.6M
Stockholders' EquityBook value
$399.7M
$11.6M
Total Assets
$539.6M
$75.4M
Debt / EquityLower = less leverage
0.22×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LAB
LAB
MSS
MSS
Q4 25
Q3 25
$129.4M
$1.1M
Q2 25
$158.6M
$775.4K
Q1 25
$150.9M
$445.4K
Q4 24
$355.7K
Q3 24
$210.6M
$588.9K
Q2 24
$269.8M
$2.1M
Q1 24
$287.1M
$9.4M
Total Debt
LAB
LAB
MSS
MSS
Q4 25
$2.6M
Q3 25
$2.6M
Q2 25
$2.6M
Q1 25
Q4 24
Q3 24
$55.2M
$2.5M
Q2 24
$55.1M
$2.6M
Q1 24
$55.0M
$2.6M
Stockholders' Equity
LAB
LAB
MSS
MSS
Q4 25
$11.6M
Q3 25
$399.7M
$10.1M
Q2 25
$424.5M
$11.7M
Q1 25
$454.6M
$12.0M
Q4 24
$10.9M
Q3 24
$489.3M
$11.2M
Q2 24
$510.3M
$10.5M
Q1 24
$577.3M
$13.3M
Total Assets
LAB
LAB
MSS
MSS
Q4 25
$75.4M
Q3 25
$539.6M
$73.3M
Q2 25
$557.0M
$77.4M
Q1 25
$579.6M
$82.7M
Q4 24
$82.7M
Q3 24
$681.5M
$82.1M
Q2 24
$708.7M
$82.4M
Q1 24
$777.7M
$44.2M
Debt / Equity
LAB
LAB
MSS
MSS
Q4 25
0.22×
Q3 25
0.26×
Q2 25
0.22×
Q1 25
Q4 24
Q3 24
0.11×
0.23×
Q2 24
0.11×
0.24×
Q1 24
0.10×
0.19×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LAB
LAB
MSS
MSS
Operating Cash FlowLast quarter
$-22.2M
$-1.7M
Free Cash FlowOCF − Capex
$-23.1M
FCF MarginFCF / Revenue
-118.1%
Capex IntensityCapex / Revenue
4.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-111.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LAB
LAB
MSS
MSS
Q4 25
$-1.7M
Q3 25
$-22.2M
$1.1M
Q2 25
$-20.7M
$-1.6M
Q1 25
$-30.3M
$1.7M
Q4 24
$1.1M
Q3 24
$-27.9M
$3.6M
Q2 24
$-39.0M
$-2.6M
Q1 24
$-62.5M
$-1.4M
Free Cash Flow
LAB
LAB
MSS
MSS
Q4 25
Q3 25
$-23.1M
Q2 25
$-22.6M
Q1 25
$-35.3M
Q4 24
Q3 24
$-30.1M
Q2 24
$-41.0M
Q1 24
$-63.3M
FCF Margin
LAB
LAB
MSS
MSS
Q4 25
Q3 25
-118.1%
Q2 25
-103.6%
Q1 25
-86.6%
Q4 24
Q3 24
-136.4%
Q2 24
-182.2%
Q1 24
-138.9%
Capex Intensity
LAB
LAB
MSS
MSS
Q4 25
Q3 25
4.5%
Q2 25
8.7%
Q1 25
12.4%
Q4 24
Q3 24
10.2%
Q2 24
8.6%
Q1 24
1.7%
Cash Conversion
LAB
LAB
MSS
MSS
Q4 25
Q3 25
Q2 25
Q1 25
1.66×
Q4 24
Q3 24
5.12×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

MSS
MSS

Perishables$14.4M52%
Nonperishables$13.2M48%

Related Comparisons